Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 5
Submit an article Journal homepage
631
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial

Pavel NemecDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
,
Zuzana ZemanovaThe Center for Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics
,
Petr KuglikDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic;Department of Medical Genetics, Faculty Hospital Brno, Czech Republic
,
Kyra MichalovaThe Center for Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics
,
Jana TajtlovaThe Center for Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics
,
Petra KaisarovaDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
,
Alexandra OltovaDepartment of Medical Genetics, Faculty Hospital Brno, Czech Republic
,
Hana FilkovaDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
,
Milena HolzerovaDepartment of Hemato-Oncology, Faculty Hospital Olomouc, Czech Republic
,
Jana BalcarkovaDepartment of Hemato-Oncology, Faculty Hospital Olomouc, Czech Republic
,
Marie JarosovaDepartment of Hemato-Oncology, Faculty Hospital Olomouc, Czech Republic
,
Jana RabasovaDepartment of Medical Genetics
,
Martina HrubaInstitute of Medical Genetics
,
Ivan Spicka1st Medical Department, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
,
Evzen GregoraDepartment of Clinical Hematology, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
,
Zdenek AdamDepartment of Internal Medicine – Hematooncology, University Hospital Brno, Czech Republic
,
Vlastimil Scudla3rd Department of Internal Medicine, Medical Faculty, Palacky University, Olomouc, Czech Republic
,
Vladimir MaisnarDepartment of Clinical Hematology, Faculty Hospital Hradec Kralove, Czech Republic
,
Miroslava SchutzovaDepartment of Hematooncology, Faculty Hospital Plzen, Czech Republic
,
Roman HajekDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic;Department of Internal Medicine – Hematooncology, University Hospital Brno, Czech RepublicCorrespondence[email protected]
& The Czech Myeloma Group show all
Pages 920-927 | Received 18 Jul 2011, Accepted 12 Oct 2011, Published online: 13 Dec 2011

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Chuanying Geng, Guangzhong Yang, Huixing Zhou, Huijuan Wang, Yanchen Li, Yun Leng, Zhiyao Zhang, Yuan Jian & Wenming Chen. (2023) Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era. Hematology 28:1.
Read now
Anna Guidetti, Claudia Paba Prada, Jacob P Laubach, Cindy Varga, Michelle E Maglio, Mary McKenney, Deborah Doss, Robert L Schlossman, Constantine Mitsiades, Teru Hideshima, Güllü T Görgün, Irene M Ghobrial, Noopur Raje, Nikhil Munshi, Kenneth C Anderson & Paul G Richardson. (2014) Pomalidomide for the treatment of relapsed and refractory multiple myeloma. Expert Opinion on Orphan Drugs 2:10, pages 1089-1108.
Read now
Fedor Kryukov, Pavel Nemec, Elena Dementyeva, Lenka Kubiczkova, Ivana Ihnatova, Eva Budinska, Jiri Jarkovsky, Sabina Sevcikova, Petr Kuglik & Roman Hajek. (2013) Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leukemia & Lymphoma 54:9, pages 1982-1988.
Read now
Nicole Wong Doo, Philip A. Thompson, H. Miles Prince, John F. Seymour, David Ritchie, Kerrie Stokes, Kate Burbury, Max Wolf, Trish Joyce & Simon J. Harrison. (2013) Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leukemia & Lymphoma 54:7, pages 1465-1472.
Read now
Ali McBride & Patricia Y Ryan. (2013) Proteasome inhibitors in the treatment of multiple myeloma. Expert Review of Anticancer Therapy 13:3, pages 339-358.
Read now

Articles from other publishers (24)

Juan Felipe Combariza, Rocío Ordúz, Claudia Agudelo, Sonia Hernandez, Ana María Madera, Guillermo León, Vladimir Avila, Leonardo Bautista, Jaime Valdés, Carlos Camargo, Víctor Sanchez, Fabián Mejía, Liliana Moreno & Carlos Ramirez. (2022) Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia. Clinical Lymphoma Myeloma and Leukemia 22:8, pages 601-607.
Crossref
Patrick W. Mellors, Moritz Binder, Rhett P. Ketterling, Patricia T. Greipp, Linda B. Baughn, Jess F. Peterson, Dragan Jevremovic, Kathryn E. Pearce, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Suzanne R. Hayman, Prashant Kapoor, Wilson I. Gonsalves, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Taxiarchis Kourelis, Rahma Warsame, John A. Lust, Nelson Leung, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar & Shaji K. Kumar. (2020) Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances 4:10, pages 2236-2244.
Crossref
Cigdem Aydin, Turgay Ulas, Ceren Hangul, Orhan Kemal Yucel, Utku Iltar, Ozan Salim, Deniz Ekinci & Sibel Berker Karauzum. (2019) Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. Indian Journal of Hematology and Blood Transfusion 36:2, pages 284-291.
Crossref
Hang Dong, Siyi Jiang, Yunfeng Fu, Yanwei Luo, Rong Gui & Jing Liu. (2019) Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma. Frontiers in Pharmacology 10.
Crossref
Lenka Sedlarikova, Bozena Bollova, Lenka Radova, Lucie Brozova, Jiri Jarkovsky, Martina Almasi, Miroslav Penka, Petr Kuglík, Viera Sandecká, Martin Stork, Ludek Pour & Sabina Sevcikova. (2018) Circulating exosomal long noncoding RNA PRINS—First findings in monoclonal gammopathies. Hematological Oncology 36:5, pages 786-791.
Crossref
Huan Wang, Xin Zhou, Jian‑Wei Zhu, Jian‑Nan Ye, Hong‑Feng Guo & Chao Sun. (2018) Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncology Letters.
Crossref
Thomas Smol, Annika Dufour, Sabine Tricot, Mathieu Wemeau, Laure Stalnikiewicz, Franck Bernardi, Christine Terr?Beno?t Ducourneau, Herv? Bisiau & Agn?s Daudignon. (2017) Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma. Molecular Cytogenetics 10:1.
Crossref
Lenka Sedlarikova, Barbora Gromesova, Veronika Kubaczkova, Lenka Radova, Jana Filipova, Jiri Jarkovsky, Lucie Brozova, Roberta Velichova, Martina Almasi, Miroslav Penka, Renata Bezdekova, Martin Stork, Zdenek Adam, Ludek Pour, Marta Krejci, Petr Kuglík, Roman Hajek & Sabina Sevcikova. (2017) Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. European Journal of Haematology 99:3, pages 223-233.
Crossref
Fedor Kryukov, Pavel Nemec, Lenka Radova, Elena Kryukova, Samuel Okubote, Jiri Minarik, Zdena Stefanikova, Ludek Pour & Roman Hajek. (2016) Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. Journal of Translational Medicine 14:1.
Crossref
Lenka Besse, Lenka Sedlarikova, Henrieta Greslikova, Renata Kupska, Martina Almasi, Miroslav Penka, Tomas Jelinek, Ludek Pour, Zdenek Adam, Petr Kuglik, Marta Krejci, Roman Hajek & Sabina Sevcikova. (2016) Cytogenetics in multiple myeloma patients progressing into extramedullary disease. European Journal of Haematology 97:1, pages 93-100.
Crossref
Yuan Jian, Xiaolei Chen, Huixing Zhou, Wanqiu Zhu, Nian Liu, Chuanying Geng & Wenming Chen. (2016) Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma. Medicine 95:19, pages e3521.
Crossref
Melissa Gaik-Ming Ooi, Sanjay de Mel & Wee Joo Chng. (2016) Risk Stratification in Multiple Myeloma. Current Hematologic Malignancy Reports 11:2, pages 137-147.
Crossref
A M Rajan & S V Rajkumar. (2015) Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer Journal 5:10, pages e365-e365.
Crossref
Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, Petr Kuglik, Martina Almasi, Miroslav Penka, Marta Krejci, Zdenek Adam, Ludek Pour, Sabina Sevcikova & Roman Hajek. (2015) Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLOS ONE 10:9, pages e0137294.
Crossref
NIAN LIU, HEBING ZHOU, GUANGZHONG YANG, CHUANYING GENG, YUAN JIAN, HUAN GUO & WENMING CHEN. (2015) Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. Oncology Letters 9:2, pages 930-936.
Crossref
Ravi Salgia. (2014) Fibroblast growth factor signaling and inhibition in non‐small cell lung cancer and their role in squamous cell tumors. Cancer Medicine 3:3, pages 681-692.
Crossref
Ji-Hun Lim, Eul-Ju Seo, Chan-Jeoung Park, Seongsoo Jang, Hyun-Sook Chi, Cheolwon Suh, Hawk Kim & Sung-Ryul Kim. (2014) Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities. European Journal of Haematology 92:4, pages 313-320.
Crossref
Julia T Geyer, Ruben Niesvizky, David S Jayabalan, Susan Mathew, Shivakumar Subramaniyam, Alexander I Geyer, Attilio Orazi & Scott A Ely. (2014) IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Modern Pathology 27:3, pages 375-381.
Crossref
Junling Zhuang, Yi Da, Hui Li, Bing Han, Xia Wan, Tienan Zhu, Miao Chen, Minghui Duan, Ying Xu, Yongqiang Zhao, Ti Shen, Yongji Wu & Daobin Zhou. (2014) Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. Leukemia Research 38:2, pages 188-193.
Crossref
Jan Smetana, Jan Frohlich, Romana Zaoralova, Vladimira Vallova, Henrieta Greslikova, Renata Kupska, Pavel Nemec, Aneta Mikulasova, Martina Almasi, Ludek Pour, Zdenek Adam, Viera Sandecka, Lenka Zahradová, Roman Hajek & Petr Kuglik. (2014) Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience. BioMed Research International 2014, pages 1-9.
Crossref
Elena Dementyeva, Fedor Kryukov, Lenka Kubiczkova, Pavel Nemec, Sabina Sevcikova, Ivana Ihnatova, Jiri Jarkovsky, Jiri Minarik, Zdena Stefanikova, Petr Kuglik & Roman Hajek. (2013) Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. Journal of Translational Medicine 11:1.
Crossref
Fedor Kryukov, Elena Dementyeva, Lenka Kubiczkova, Jiri Jarkovsky, Lucie Brozova, Jakub Petrik, Pavel Nemec, Sabina Sevcikova, Jiri Minarik, Zdena Stefanikova, Petr Kuglik & Roman Hajek. (2013) Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics 102:4, pages 243-249.
Crossref
Bo-Hee Lee, Seung Hwan Shin, Chang-Ki Min, Ho-Young Yhim, Jae-Yong Kwak & Jeong-A Kim. (2013) Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy. International Journal of Hematology 97:5, pages 634-639.
Crossref
Jan Smetana, Kristina Berankova, Romana Zaoralova, Pavel Nemec, Henrieta Greslikova, Renata Kupska, Aneta Mikulasova, Jan Frohlich, Sabina Sevcikova, Lucie Zahradova, Marta Krejci, Viera Sandecka, Martina Almasi, Petra Kaisarova, Hana Melicharova, Zdenek Adam, Miroslav Penka, Jiri Jarkovsky, Arthur Jurczyszyn, Roman Hajek & Petr Kuglik. (2013) Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib. Clinical Lymphoma Myeloma and Leukemia 13:2, pages 123-130.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.